What is Thermo Fisher Scientific Inc. (TMO) DCF Fair Value and Intrinsic Value in 2026?

Thermo Fisher Scientific Inc. (TMO) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is Thermo Fisher Scientific Inc.'s historical Return on Invested Capital (ROIC) and Moat Rating?

Thermo Fisher Scientific Inc. operates in the Healthcare sector (Diagnostics & Research) with an economic moat rating of WIDE. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is Thermo Fisher Scientific Inc.'s financial health rating and Piotroski F-Score?

Thermo Fisher Scientific Inc.'s balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor Thermo Fisher Scientific Inc. (TMO) for quarterly SEC filing thesis breaks?

LocalAlpha audits Thermo Fisher Scientific Inc.'s 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksTMO

TMO

Thermo Fisher Scientific IncHealthcare / Diagnostics & ResearchINTACT

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Share Price

$612.18

52W: $435.27 - $647

DCF Fair Value

$276.44

-121.5% Premium

Thesis Hub

P/E (TTM)

32.9x

ROIC

14.1%

Operating Margin

18.8%

FCF Yield

2.8%

Debt / Equity

0.81x

Piotroski Score

8/9

Altman Z-Score

3.18

Market Cap

$226.4B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($276.44)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$276.44

MOS Buy Target (-25%)

$207.33

Valuation Overlays: DCF Fair Value ($276.44) 25% MOS Buy Target ($207.33) Revised Graham ($384.92) Graham Number ($244.05)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$612.18

DCF Fair Value

$276.48

-121.4% Premium

Starting Free Cash Flow ($M)$6,237M

$100M$6,237M (Reported)$50,000M

Stage 1 Growth (Years 1-5)9.4%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)$38,400M

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$59.6B

PV of Terminal Value

$81.1B

Implied Enterprise Value

$140.7B

Implied Equity Value

$102.3B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$6,823	$7,465	$8,166	$8,934	$9,774	$10,214	$10,673	$11,154	$11,655	$12,180
Present Value (PV)	$6,260	$6,283	$6,306	$6,329	$6,352	$6,090	$5,839	$5,598	$5,366	$5,145

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-150.8% Premium

$244.05

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $18.58BVPS: $142.47

Revised Graham Formula-59% Premium

$384.92

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings2.6% Yield

$16.01 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $5.9BYield: 2.6%

Reverse DCF: Market Growth Expectation

FAIR BARRIER

13.5% CAGR (Next 10 Yrs)

At the current price of $612.18, the market is assuming the business will compound Free Cash Flow at 13.5% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

ℹ Fair expectations: Requires steady execution.

Autonomous Thesis Underwriting

Surveil TMO with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for Thermo Fisher Scientific Inc. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 18.8% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track TMO & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: Thermo Fisher Scientific Inc (TMO) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Thermo Fisher Scientific Inc.

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, Thermo Fisher Scientific Inc has an estimated DCF intrinsic fair value of $276.44 per share compared to its current market price of $612.18. This represents an estimated 121.5% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $244.05.